Isomorphic Labs, an artificial intelligence drug discovery startup founded by former Google DeepMind chief Demis Hassabis, has raised a $5 billion Series C, the manufacturer stated on Tuesday.

Isomorphic's round comes three-and-a-half months after Hassabis stepped back as CEO of DeepMind, Google's AI lab, which he co-founded before the Significant Tech giant acquired it in 2014.

In a recent development, the round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz, with investment from Alphabet, Google's parent. The fresh funds will help fund the design and development of latest medicines using AI.

Drug discovery startups have seen record funding poured into them by investors in 2026 as companies look to capitalize on advances in AI. OpenAI and Anthropic have also been investing in tools to develop new medicines using the technology.

Hassabis has been CEO of Isomorphic Labs since the startup spun out of DeepMind in 2021.

"When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI," said Hassabis.

"This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients," he added.

Isomorphic is building a proprietary drug design engine and therapeutic candidate pipeline designed with AI, which it states will help it deliver the next generation of medicines.

Anthropic announced it was launching an AI drug discovery program in June and OpenAI partnered with Novo Nordisk in April.

Drug discovery startups have raised $23.2 billion in 2026, according to deal-counting platform Dealroom, a record figure.

Isomorphic last raised in May, with a $2.1 billion Series B.

→ Read original article